These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 26986047)

  • 1. Nonthermal Ablation by Using Intravascular Oxygen Radical Generation with WST11: Dynamic Tissue Effects and Implications for Focal Therapy.
    Kimm SY; Tarin TV; Monette S; Srimathveeravalli G; Gerber D; Durack JC; Solomon SB; Scardino PT; Scherz A; Coleman J
    Radiology; 2016 Oct; 281(1):109-18. PubMed ID: 26986047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WST11 Vascular Targeted Photodynamic Therapy Effect Monitoring by Multispectral Optoacoustic Tomography (MSOT) in Mice.
    Neuschmelting V; Kim K; Malekzadeh-Najafabadi J; Jebiwott S; Prakash J; Scherz A; Coleman JA; Kircher MF; Ntziachristos V
    Theranostics; 2018; 8(3):723-734. PubMed ID: 29344301
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment Effects of WST11 Vascular Targeted Photodynamic Therapy for Urothelial Cell Carcinoma in Swine.
    Murray KS; Winter AG; Corradi RB; LaRosa S; Jebiwott S; Somma A; Takaki H; Srimathveeravalli G; Lepherd M; Monette S; Kim K; Scherz A; Coleman JA
    J Urol; 2016 Jul; 196(1):236-43. PubMed ID: 26860792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endoscopic vascular targeted photodynamic therapy with the photosensitizer WST11 for benign prostatic hyperplasia in the preclinical dog model.
    Chevalier S; Cury FL; Scarlata E; El-Zayat E; Hamel L; Rocha J; Zouanat FZ; Moussa S; Scherz A; Elhilali M; Anidjar M
    J Urol; 2013 Nov; 190(5):1946-53. PubMed ID: 23680311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical study of the novel vascular occluding agent, WST11, for photodynamic therapy of the canine prostate.
    Chevalier S; Anidjar M; Scarlata E; Hamel L; Scherz A; Ficheux H; Borenstein N; Fiette L; Elhilali M
    J Urol; 2011 Jul; 186(1):302-9. PubMed ID: 21600602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy.
    Moore CM; Azzouzi AR; Barret E; Villers A; Muir GH; Barber NJ; Bott S; Trachtenberg J; Arumainayagam N; Gaillac B; Allen C; Schertz A; Emberton M
    BJU Int; 2015 Dec; 116(6):888-96. PubMed ID: 24841929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic antitumor protection by vascular-targeted photodynamic therapy involves cellular and humoral immunity.
    Preise D; Oren R; Glinert I; Kalchenko V; Jung S; Scherz A; Salomon Y
    Cancer Immunol Immunother; 2009 Jan; 58(1):71-84. PubMed ID: 18488222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WST11, a novel water-soluble bacteriochlorophyll derivative; cellular uptake, pharmacokinetics, biodistribution and vascular-targeted photodynamic activity using melanoma tumors as a model.
    Mazor O; Brandis A; Plaks V; Neumark E; Rosenbach-Belkin V; Salomon Y; Scherz A
    Photochem Photobiol; 2005; 81(2):342-51. PubMed ID: 15623318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States.
    Taneja SS; Bennett J; Coleman J; Grubb R; Andriole G; Reiter RE; Marks L; Azzouzi AR; Emberton M
    J Urol; 2016 Oct; 196(4):1096-104. PubMed ID: 27291652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of localized prostate cancer by vascular-targeted photodynamic therapy with WST11].
    Lebdai S; Martin F; Bigot P; Azzouzi AR
    Prog Urol; 2014 Nov; 24(14):911-4. PubMed ID: 25195031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular targeted photodynamic therapy with TOOKAD® Soluble (WST11) in localized prostate cancer: efficiency of automatic pre-treatment planning.
    Betrouni N; Boukris S; Benzaghou F
    Lasers Med Sci; 2017 Aug; 32(6):1301-1307. PubMed ID: 28569345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TOOKAD(®) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.
    Azzouzi AR; Barret E; Moore CM; Villers A; Allen C; Scherz A; Muir G; de Wildt M; Barber NJ; Lebdai S; Emberton M
    BJU Int; 2013 Oct; 112(6):766-74. PubMed ID: 24028764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stiffening of rabbit corneas by the bacteriochlorophyll derivative WST11 using near infrared light.
    Marcovich AL; Brandis A; Daphna O; Feine I; Pinkas I; Goldschmidt R; Kalchenko V; Berkutzki T; Wagner HD; Salomon Y; Scherz A
    Invest Ophthalmol Vis Sci; 2012 Sep; 53(10):6378-88. PubMed ID: 22871842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Robotically Assisted Sonic Therapy as a Noninvasive Nonthermal Ablation Modality: Proof of Concept in a Porcine Liver Model.
    Smolock AR; Cristescu MM; Vlaisavljevich E; Gendron-Fitzpatrick A; Green C; Cannata J; Ziemlewicz TJ; Lee FT
    Radiology; 2018 May; 287(2):485-493. PubMed ID: 29381870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Permanent occlusion of feeding arteries and draining veins in solid mouse tumors by vascular targeted photodynamic therapy (VTP) with Tookad.
    Madar-Balakirski N; Tempel-Brami C; Kalchenko V; Brenner O; Varon D; Scherz A; Salomon Y
    PLoS One; 2010 Apr; 5(4):e10282. PubMed ID: 20421983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-time monitoring of radiofrequency ablation and postablation assessment: accuracy of contrast-enhanced US in experimental rat liver model.
    Wu H; Wilkins LR; Ziats NP; Haaga JR; Exner AA
    Radiology; 2014 Jan; 270(1):107-16. PubMed ID: 23912621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination radiofrequency ablation with intratumoral liposomal doxorubicin: effect on drug accumulation and coagulation in multiple tissues and tumor types in animals.
    Ahmed M; Liu Z; Lukyanov AN; Signoretti S; Horkan C; Monsky WL; Torchilin VP; Goldberg SN
    Radiology; 2005 May; 235(2):469-77. PubMed ID: 15858089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irreversible electroporation: evaluation of nonthermal and thermal ablative capabilities in the porcine kidney.
    Olweny EO; Kapur P; Tan YK; Park SK; Adibi M; Cadeddu JA
    Urology; 2013 Mar; 81(3):679-84. PubMed ID: 23290141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irreversible electroporation: treatment effect is susceptible to local environment and tissue properties.
    Ben-David E; Ahmed M; Faroja M; Moussa M; Wandel A; Sosna J; Appelbaum L; Nissenbaum I; Goldberg SN
    Radiology; 2013 Dec; 269(3):738-47. PubMed ID: 23847254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal tissue ablation with irreversible electroporation: preliminary results in a porcine model.
    Deodhar A; Monette S; Single GW; Hamilton WC; Thornton R; Maybody M; Coleman JA; Solomon SB
    Urology; 2011 Mar; 77(3):754-60. PubMed ID: 21111458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.